HYAL3 was additionally associated with several types of infiltrating immunocytes in BLCA, including Th cells, T cells, CD8+ T cells, cytotoxic cells, B cells, etc. These data indicate that HYAL3 might serve as a biomarker for BLCA diagnosis and treatment in the future. The gene discussed is CD8A; the disease is bladder transitional cell carcinoma.